MEDI 0457

Drug Profile

MEDI 0457

Alternative Names: INO-3112; INO-9012/VGX-3100; MEDI-0457; VGX-3100/INO-9012

Latest Information Update: 13 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals; MedImmune; University of Pennsylvania
  • Class Cancer vaccines; DNA vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cervical cancer; Head and neck cancer

Most Recent Events

  • 02 Jun 2017 Immunogenicity data from a phase I/II trial in Head and neck cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 26 May 2017 Phase-I/II clinical trials in Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IM) (NCT03162224)
  • 15 Mar 2017 MedImmune plans a phase I/II trial of MEDI 0457 (Combination therapy) for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top